Replies to post #61873 on Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

That is my recollection as well.

[Maciste]

That's a fact sir. Very well said.

[zuize]

Harvey Berger was completely lying through his teeth, some here still ... pray that Berger keeps control of Ariad.

fully agree with you on this and don't expect any response from those "some" as the twos are totally blind to see what really going on and too deaf to hear the reasonable voice from others.


Regarding to this part:

Remarkably, even though Adam Feuerstein turned out to be 100% correct and ... some here still call Feuestein a shill...

Adam F. was correct before the Crash.
But is it really remarkable or simply pure-luck??? Is it possible for Adam, a person without science background/medical training to see the toxicity issue in Pona before others, or simply because the shorts who paid him for writing the article turned out to be correct and very lucky in their bets over FDA's hash decision in pulling Pona from the market, then only 9 weeks later having their decision reverted and Pona back to the market???

You sounded like Adam F. and the shorts were the winners, but if you looked closely at the change of short interest data in the couple months before and after the Crash, you would see that the shorts were losing money as much as the longs for they shorted over 25 million shares in the price range between $2s -> $5s/shares and then caught off-guard by FDA decision in having Pona back to the market. Given the existing short interest of 45 million shares while ARIA being traded @ $9s/share with the upcoming proxy for ousting HB and the highly possible BO, the shorts are going to lose much more, while those new investors purchasing shares after the crash are the one benefit the most from the Crash.

Regarding to Adam F. credibility, simply take a look at this article in which he stated that the combination of Novartis's ABL001+Tasignia would drive Ariad's Pona out of the market, and AP26113 was basically no match to Novartis's LDK378. And look at what happen to Pona, the drug getting approved in many countries with sell increased quarter by quarter, while '113 clinical data shows it's superior over Novartis's LDK378.


Sorry that I need to go now and need to stop here ... :)